Validation of IgA nephropathy diagnosis in the Swedish Renal Registry
(2024) In BMC Nephrology 25(1).- Abstract
Aim: The Swedish Renal Registry (SRR) is a unique national quality registry that monitors the clinical trajectory of patients with chronic kidney disease (CKD). We have validated the biopsy data registered in the SRR for IgA Nephropathy (IgAN) diagnosis. Methods: In total 25% of all patients (n = 142), registered with IgAN in the SRR after having performed a kidney biopsy during 2015–2019, were randomly selected. We obtained original biopsy and medical records for 139 (98%) patients. We evaluated the IgAN diagnosis using a standardized template, calculated its positive predictive value (PPV) with 95% confidence interval (CI) and reported clinical features at the time of diagnosis. Results: A histological and clinical diagnosis of IgAN... (More)
Aim: The Swedish Renal Registry (SRR) is a unique national quality registry that monitors the clinical trajectory of patients with chronic kidney disease (CKD). We have validated the biopsy data registered in the SRR for IgA Nephropathy (IgAN) diagnosis. Methods: In total 25% of all patients (n = 142), registered with IgAN in the SRR after having performed a kidney biopsy during 2015–2019, were randomly selected. We obtained original biopsy and medical records for 139 (98%) patients. We evaluated the IgAN diagnosis using a standardized template, calculated its positive predictive value (PPV) with 95% confidence interval (CI) and reported clinical features at the time of diagnosis. Results: A histological and clinical diagnosis of IgAN was confirmed in 132 of the 139 patients, yielding a PPV of 95% (95% CI 90–98%). Median age was 46 years (range: 18–85) and the male:female ratio was 2.1:1. The median creatinine level was 123 µmol/L, with a corresponding estimated glomerular filtration rate (eGFR) level of 51 mL/min/1.73m2. Histological features of IgA deposits were seen in all patients, hypercellularity in 102/132 (77.2%), C3 deposits in 98/132 (72.4%) and C1q deposits in 27/132 (20.5%) of the cases. Conclusion: Validating data is not research per se, but continuous validation of medical registries is an important feature necessary to ensure reliable data and the foundation of good epidemiological data for future research. Our validation showed a high PPV (95%) for IgAN diagnosis registered in the SRR. Clinical characteristics were consistent with previous reports. The biopsy data in the SRR will be a valuable resource in future IgAN research.
(Less)
- author
- Rehnberg, Johanna ; Segelmark, Mårten LU ; Ludvigsson, Jonas F. and Emilsson, Louise
- organization
- publishing date
- 2024-12
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- IgA nephropathy, Kidney biopsy, Swedish Renal Registry, Validation
- in
- BMC Nephrology
- volume
- 25
- issue
- 1
- article number
- 78
- publisher
- BioMed Central (BMC)
- external identifiers
-
- pmid:38438966
- scopus:85186551952
- ISSN
- 1471-2369
- DOI
- 10.1186/s12882-024-03512-2
- language
- English
- LU publication?
- yes
- id
- 5ebfc048-a0f7-4ed5-b8e0-c10c753d2105
- date added to LUP
- 2024-03-14 11:43:57
- date last changed
- 2024-04-25 08:21:38
@article{5ebfc048-a0f7-4ed5-b8e0-c10c753d2105,
abstract = {{<p>Aim: The Swedish Renal Registry (SRR) is a unique national quality registry that monitors the clinical trajectory of patients with chronic kidney disease (CKD). We have validated the biopsy data registered in the SRR for IgA Nephropathy (IgAN) diagnosis. Methods: In total 25% of all patients (n = 142), registered with IgAN in the SRR after having performed a kidney biopsy during 2015–2019, were randomly selected. We obtained original biopsy and medical records for 139 (98%) patients. We evaluated the IgAN diagnosis using a standardized template, calculated its positive predictive value (PPV) with 95% confidence interval (CI) and reported clinical features at the time of diagnosis. Results: A histological and clinical diagnosis of IgAN was confirmed in 132 of the 139 patients, yielding a PPV of 95% (95% CI 90–98%). Median age was 46 years (range: 18–85) and the male:female ratio was 2.1:1. The median creatinine level was 123 µmol/L, with a corresponding estimated glomerular filtration rate (eGFR) level of 51 mL/min/1.73m<sup>2</sup>. Histological features of IgA deposits were seen in all patients, hypercellularity in 102/132 (77.2%), C3 deposits in 98/132 (72.4%) and C1q deposits in 27/132 (20.5%) of the cases. Conclusion: Validating data is not research per se, but continuous validation of medical registries is an important feature necessary to ensure reliable data and the foundation of good epidemiological data for future research. Our validation showed a high PPV (95%) for IgAN diagnosis registered in the SRR. Clinical characteristics were consistent with previous reports. The biopsy data in the SRR will be a valuable resource in future IgAN research.</p>}},
author = {{Rehnberg, Johanna and Segelmark, Mårten and Ludvigsson, Jonas F. and Emilsson, Louise}},
issn = {{1471-2369}},
keywords = {{IgA nephropathy; Kidney biopsy; Swedish Renal Registry; Validation}},
language = {{eng}},
number = {{1}},
publisher = {{BioMed Central (BMC)}},
series = {{BMC Nephrology}},
title = {{Validation of IgA nephropathy diagnosis in the Swedish Renal Registry}},
url = {{http://dx.doi.org/10.1186/s12882-024-03512-2}},
doi = {{10.1186/s12882-024-03512-2}},
volume = {{25}},
year = {{2024}},
}